Search

everythinglearnresearchcommunity

for

Search:↓

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

Free Testosterone Index, bioavailable testosterone, and androstenedione are the most accurate for diagnosing excess male hormones in PCOS.

Chinese women with PCOS have higher androgen levels, which change with age and weight.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Long-term diabetes is linked to lower prostate cancer risk.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

Childhood and adult height, and early immune-related hospitalizations increase testicular cancer risk, while baldness, larger families, and sports reduce it.

Certain genetic markers on the Y-chromosome may influence prostate cancer risk in Iraqi males.

Simple methods using DHT levels effectively assess compliance.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Combined finasteride and anastrozole therapy effectively treats BPH, influenced by hormone imbalances and genetics.

Researchers found four natural compounds that can change DHT levels in prostate cancer cells.

SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.

Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

Androgen levels do not determine the type of PCOS symptoms in young females.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

Finasteride may cause lasting sexual and mental health issues, and genetic screening could help prevent them.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Genetic variations may affect how well finasteride works for BPH patients.

SLCO genes may predict prostate cancer mortality risk, and lifestyle changes improve health in advanced prostate cancer.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.

Low PON1 levels may indicate and predict the severity of hair loss.

Long-term antiandrogen use may increase aggressive prostate cancer risk.

The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.

The HCR gene contributes to psoriasis risk.

The new method found new shared genetic areas linked to both Type 2 Diabetes and Prostate Cancer.